JAGUAR HEALTH, INC. Fair Value Adjustment of Warrants
JAGUAR HEALTH, INC. (JAGX) reported Fair Value Adjustment of Warrants of $23.89 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-04-03.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:FairValueAdjustmentOfWarrants · last filed 2020-04-03
- JAGUAR HEALTH, INC. fair value adjustment of warrants for the quarter ending 2017-12-31 was -$59.22K.
- JAGUAR HEALTH, INC. fair value adjustment of warrants for the quarter ending 2017-09-30 was -$388.80K.
- JAGUAR HEALTH, INC. fair value adjustment of warrants for the quarter ending 2017-06-30 was -$700.74K.
- JAGUAR HEALTH, INC. fair value adjustment of warrants for the quarter ending 2017-03-31 was $453.42K.
- JAGUAR HEALTH, INC. fair value adjustment of warrants for fiscal 2018 was $23.89K.
- JAGUAR HEALTH, INC. fair value adjustment of warrants for fiscal 2017 was -$695.34K, a 1709.59% decline from fiscal 2016.
- JAGUAR HEALTH, INC. fair value adjustment of warrants for fiscal 2016 was $43.20K, a 91.39% decline from fiscal 2015.
- JAGUAR HEALTH, INC. fair value adjustment of warrants for fiscal 2015 was $501.62K.
| Period end | Fair Value Adjustment of Warrants 3 month | Fair Value Adjustment of Warrants 6 month | Fair Value Adjustment of Warrants 9 month | Fair Value Adjustment of Warrants 12 month |
|---|---|---|---|---|
| 2018-12-31 | $23.89K 10-K · filed 2020-04-03 | |||
| 2017-12-31 | -$59.22K derived: 10-K 12 month − 10-Q 9 month · filed 2018-04-09 | -$448.02K derived: sum of 2 quarters · filed 2018-04-09 | -$1.15M derived: sum of 3 quarters · filed 2018-04-09 | -$695.34K 10-K · filed 2018-04-09 |
| 2017-09-30 | -$388.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-20 | -$1.09M derived: sum of 2 quarters · filed 2017-11-20 | -$636.12K 10-Q · filed 2017-11-20 | |
| 2017-06-30 | -$700.74K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2017-08-09 | -$247.32K 10-Q · filed 2017-08-09 | ||
| 2017-03-31 | $453.42K 10-Q/A · filed 2017-06-23 | |||
| 2016-12-31 | $43.20K 10-K · filed 2018-04-09 | |||
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $0.00 derived: sum of 2 quarters · filed 2017-02-15 | $173.10K derived: sum of 3 quarters · filed 2017-02-15 | $501.62K 10-K · filed 2017-02-15 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | $173.10K derived: sum of 2 quarters · filed 2016-11-14 | $501.62K 10-Q · filed 2016-11-14 | |
| 2015-06-30 | $173.10K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | $501.62K 10-Q · filed 2016-08-15 | ||
| 2015-03-31 | $328.52K 10-Q · filed 2016-05-10 | |||
| 2014-12-31 | -$51.42K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |